Compare ADNT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADNT | HRMY |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 2.0B |
| IPO Year | N/A | 2020 |
| Metric | ADNT | HRMY |
|---|---|---|
| Price | $19.25 | $38.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | $21.90 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 1.2M | 802.8K |
| Earning Date | 01-27-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | ★ $14,535,000,000.00 | $825,944,000.00 |
| Revenue This Year | $1.36 | $23.11 |
| Revenue Next Year | $2.11 | $16.15 |
| P/E Ratio | ★ N/A | $12.26 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $10.04 | $25.52 |
| 52 Week High | $26.16 | $40.93 |
| Indicator | ADNT | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 66.02 |
| Support Level | $18.69 | $38.12 |
| Resistance Level | $19.37 | $40.87 |
| Average True Range (ATR) | 0.62 | 1.25 |
| MACD | 0.18 | -0.07 |
| Stochastic Oscillator | 78.41 | 65.10 |
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.